COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Seraxis Wins Maryland Stem Cell Research Fund Grant to Accelerate Development of Allogenetically Compatible Pancreatic Islet Replacement Therapy for Functional Cure of T1D
Seraxis, Inc. awarded $400,000 MSCRF grant to advance SR-03 cell line for diabetes treatment. Meeting at ADA Annual Meeting in Orlando -
COMMUNIQUÉ DE PRESSE
Peerless Pump Company's FireConnect(R) Product Achieves FM Approval According to FM Standard 1330 Fire Pump Monitoring and Automated Testing
Peerless Pump Company's FireConnect® product receives FM approval according to Standard 1330, showcasing advanced remote monitoring capabilities for fire protection systems -
COMMUNIQUÉ DE PRESSE
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment -
-
-
COMMUNIQUÉ DE PRESSE
2CRSi SA: Information mensuelle relative au nombre total de droits de vote Et d’actions composant le capital social au 31 mai 2024
2CRSi communique les chiffres du nombre total d'actions et de droits de vote au 31/05/2024. Le groupe conçoit des serveurs haute performance et éco-responsables, réalisant un CA de 184M€ en 2022-2023 -
COMMUNIQUÉ DE PRESSE
2CRSi SA: Monthly information regarding the total number of voting rights and shares comprising the share capital as of April 30, 2024
2CRSi Group reports monthly voting rights and shares information as of April 30, 2024. The French company specializes in designing, producing, and marketing high-performance servers -
COMMUNIQUÉ DE PRESSE
2CRSi SA: Information mensuelle relative au nombre total de droits de vote Et d’actions composant le capital social au 31 mai 2024
2CRSi SA communique sur le nombre total de droits de vote et d'actions au 31 mai 2024. Le Groupe 2CRSi est spécialisé dans les serveurs informatiques haute performance et éco-responsables
